“I Thought I Was Losing It”: Nisha Patel’s Perimenopause Wake-Up Call—and the Simple Changes That Helped

Should the Military Screen Testosterone Levels? An Endocrinologist Explains

Defense Secretary Pete Hegseth announced a new testosterone-deficiency screening program for service members, but endocrinologist and former military doctor Dr. Karl Nadolsky says the science doesn’t support universal testing in people without symptoms. In this episode, we break down who should be evaluated, why obesity/sleep apnea and certain injuries or medications can lower testosterone, and what risks come with unnecessary testosterone replacement therapy (including infertility). 00:00 intro 00:01:00 Meet Dr. Karl Nadolsky (endocrinologist, former military physician) 00:02:02 Full clip: Pete Hegseth explains annual testing for 30+; optional under 30 00:04:31 What testosterone does/doesn’t do for performance; who truly benefits from TRT 00:05:30 How common is “true” hypogonadism vs functional low T (obesity/sleep apnea/diabetes) 00:06:48 Why widespread screening isn’t recommended; lack of evidence for better outcomes 00:08:44 Medication/injury causes: opioids, TBI, blast/testicular trauma; why targeted screening fits 00:11:59 Main risks: false positives, wrong timing/conditions for labs, unnecessary anxiety/cost 00:13:38 Proper workup: treat root causes first; don’t miss pituitary disease or sleep apnea 00:14:06 TRT tradeoffs: fertility suppression, potential long-term dependence; steroid/male-clinic pitfalls 00:16:16 Women and testosterone: testing mostly for high levels; limited menopause libido use 00:19:29 Military endocrinology + why expert input/task force matters for policy 00:22:15 Practical alternative: checkbox-based risk triggers and symptom screening at annual physicals 00:23:34 Closing: keep politics out; follow data and build evidence-based protocols

Are Peptides Safe? What a doctor Says About BPC-157, TB-500, and Buying Peptides Online

Host Kari Beal interviews Dr. George Ibrahim about the surge in peptide use for injury recovery, energy, weight loss, and more, plus why many peptides aren’t FDA-approved and have limited human data. They break down common peptides (BPC-157, TB-500, CJC-1295/ipamorelin), discuss safety and cancer/angiogenesis concerns, and explain why buying “research peptides” online can be risky. 00:00 intro 00:01 BPC-157 & TB-500 explained (repair/cleanup crews); angiogenesis + cancer concern setup. 00:03 What a peptide is; how structure drives function (key/receptor). 00:05 Evidence overview (animal vs limited human); why combine BPC-157 + TB-500. 00:07 Safety in practice: “peptide flush” and minor reactions. 00:08 Cancer-risk discussion; screening for cancer history. 00:10 Quality control: pharmacy “human-use” vs online “research” peptides; contamination/dosing risks. 00:12 How to tell: if you can buy it yourself online, it’s not human-use. 00:14 “Best” peptide pick: CJC-1295 + ipamorelin; growth-hormone support + realistic timeline. 00:17 Cost estimates; prioritizing hormones, then GH support. 00:18 Why few human trials (patents/funding). 00:20 FDA/compounding outlook; regulation and safety hopes. 00:22 Social media hype; questions to ask a doctor; special cautions (GLP-1s, tanning peptides). 00:24 More peptide uses (GHK-Cu for brain + hair/skin/nails); closing + correction (“endotoxins”).

How close are we to a cure for Hunter Syndrome?

A new FDA-approved treatment for Hunter syndrome (MPS II) is giving families hope, but it’s not a cure. We explore how close researchers may be to a cure, including promising gene therapy clinical trials, and what experts say still needs long-term study. 00:00 intro 00:45 How this story began: a mom reaches out about newly approved Avlayah. 01:03 Why it matters: therapy designed to cross the blood-brain barrier. 01:20 The emotional center: two moms bond while navigating the same diagnosis. 02:23 Hunter syndrome (MPS II) explained: missing enzyme, sugar buildup, organ/brain damage. 03:40 How the “next-gen” enzyme replacement works using an enzyme transport vehicle. 04:16 Early impact: reported behavioral/physical improvements and infusion-center support. 05:36 “Not a cure” → what a cure could look like; intro to gene therapy. 06:23 London trial spotlight: one-time ex vivo gene therapy; early (anecdotal) improvements. https://www.gosh.nhs.uk/news/gosh-manufactures-new-gene-therapy-for-rare-condition/ 08:01 U.S. clinical trial in New Jersey: timelines and what’s still unknown. https://clinicaltrials.gov/study/NCT07236606 08:48 Physician Assistant Laura Buch: long-term durability, dosing questions, and rare-disease trial limits. 10:03 Advocacy + how to find trials on ClinicalTrials.gov; closing thoughts. https://clinicaltrials.gov/study/NCT03566043

Psychedelic Therapy: Why so many patients are asking for the option

The federal government is fast-tracking some psychedelic-based medicines for research and development. Emergency physician Dr. Jonathan Leak explains how these therapies may work in the brain and if they’re safe. 00:00 — Fire captain recounts suicidal crisis; psilocybin changes his outlook and family life 00:36 — Intro: what psychedelics might do (neurotransmitters/neuroplasticity) and the safety question 00:54 — Why now: executive order to speed development; focus on treatment-resistant depression, PTSD, addiction 01:23 — Arizona psilocybin trial for first responders; content warning for sensitive topics 02:05 — Mark Herman’s story: chronic trauma, “fight or flight,” and seeking relief 03:01 — Research barriers from past criminalization; trial details and demand/waitlist 04:22 — Career risks/stigma for officers; underground use; dosing and safety concerns 05:01 — Black market concerns; funding push; hopes for right-to-try and guardrails as access expands 07:20 — Interview begins: Dr. Leak’s credentials; ketamine currently used in psychedelic therapy 08:15 — What drugs are discussed: psilocybin, ibogaine, methylone/MDMA 09:00 — Evidence/history; why these may help PTSD, depression, addiction 10:53 — How they may work: receptors + neuroplasticity + psychedelic experience; importance of therapy integration 12:36 — Brain connectivity shifts; new pathways; how psilocybin is dosed and how long sessions last 15:01 — Patents/formulations; molecule tweaks vs process patents 16:02 — MDMA/methylone differences; trauma processing and study outcomes; need for certified care 18:08 — Clinic model questions; side effects, monitoring, and scaling sessions safely

Musician Carnie Wilson Talks Tardive Dyskinesia (TD): Signs, Stigma, and Getting Diagnosed

Musician Carnie Wilson is raising awareness about tardive dyskinesia (TD), an uncontrolled movement disorder that often goes undiagnosed. She shares why she’s advocating for screening, how stigma can keep people silent, and where listeners can find support and resources.  00:00 – intro 00:01:05 – What TD is: common symptoms (face/lips, chewing-like movements, eye twitch). 00:01:29 – Main cause: dopamine receptor–blocking meds (often antipsychotics); risk factors + generations of meds. 00:02:21 – Why TD is missed: many cases undiagnosed; importance of recognizing symptoms. 00:02:42 – Carnie on speaking up, getting screened, and how diagnosis can change lives. 00:04:53 – “Connecting with Carnie” campaign + where to find resources (connectingwithcarney.com). 00:05:24 – Bell’s palsy story as a way to relate to visible conditions and shame/stares. 00:07:10 – What helps diagnosis: noticing changes, telling your healthcare provider, rejecting shame. 00:09:33 – How TD impacts daily life (driving, sleep, leaving home) + real patient stories. 00:10:17 – Carnie on depression/addiction, stigma, and checking in on mental health. 00:14:23 – Medication/research question; Carnie points listeners back to medical resources. 00:16:18 – Why this cause matters to her: family experience with mental illness + compassion. 00:19:10 – Specific symptoms to watch for + encouragement to seek help. 00:20:30 – Final call to visit the campaign site; thanks and outro.